Gene

IFNGR1

interferon gamma receptor 1

Explore in graph →CI-GENE-00005427HGNC:5439 ENSG00000027697 NCBI 3459 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (1)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
IFNGR1 Loss1
Ipilimumab	Melanoma	Predictive	D	Supports Resistance	2	accepted	EID12142 C57BL/6 mice were inoculated with B16/BL6 tumour cells and treated with anti-CTLA-4 to assess in-vivo effects of IFNGR1 knockdown on tumour growth. All untreated mice with wildtype scramble shRNA-tran… (full text at CIViC) PMID 27667683 · Gao et al., 2016 · Open in CIViC	civic

Cohorts

Alteration frequency by cohort (27)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved27 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Breast Cancer (MSK, Clinical Cancer Res 2020) brca_pareja_msk_2020	Invasive Breast Carcinoma	Ssm	4	60

Literature

Linked publications (1)

25 per page, newest first.

pubmedPublishedShowing 1–1 of 1 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy.
· Cell · 2016 · PMID 27667683 · validated civic_curation pubmed